Alimera is a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. Their products, ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg and YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg, can reduce the recurrence of disease, enabling patients to maintain vision longer with fewer injections. In the U.S., ILUVIEN is available for diabetic macular edema (DME) patients and YUTIQ for patients with chronic non-infectious uveitis affecting the posterior segment. ILUVIEN is also available in several European countries and the Middle East for both DME and recurrent non-infectious uveitis affecting the posterior segment.
Brands: ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg
YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18mg